Trial Outcomes & Findings for Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer (NCT NCT01656460)
NCT ID: NCT01656460
Last Updated: 2020-07-22
Results Overview
Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Serious adverse events will be captured from the time the patient signs consent until 12 weeks after the last SBRT. DLTS: defined in protocol as: Dose limiting toxicities will be defined as grade 3 or greater treatment related pneumonitis, cardiac toxicity, bronchial injury or chest wall pain during or within 4 weeks of completion of SBRT.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
12 participants
Primary outcome timeframe
3 months
Results posted on
2020-07-22
Participant Flow
Participant milestones
| Measure |
Stereotactic Radiation Dose Level 1
Radiation: Stereotactic radiation Arm 1 Dose Levels Dose per Fraction Total Dose
1 8 Gy 16 Gy
|
Stereotactic Radiation Dose Level 2
Radiation: Stereotactic radiation Arm 2 Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
|
Stereotactic Radiation Dose Level 3
Radiation: Stereotactic radiation Arm 3 Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
|
Stereotactic Radiation Dose Level 4
Radiation: Stereotactic radiation Arm 4 Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
3
|
3
|
3
|
|
Overall Study
COMPLETED
|
3
|
3
|
3
|
3
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer
Baseline characteristics by cohort
| Measure |
Stereotactic Radiation
n=12 Participants
stereotactic
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
5 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
7 Participants
n=5 Participants
|
|
Age, Continuous
|
63.9 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
12 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 3 monthsAny toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Serious adverse events will be captured from the time the patient signs consent until 12 weeks after the last SBRT. DLTS: defined in protocol as: Dose limiting toxicities will be defined as grade 3 or greater treatment related pneumonitis, cardiac toxicity, bronchial injury or chest wall pain during or within 4 weeks of completion of SBRT.
Outcome measures
| Measure |
Arm 1-Stereotactic Radiation Dose Level 1
n=3 Participants
Radiation: Stereotactic radiation Arm 1 Dose Levels Dose per Fraction Total Dose
1 8 Gy 16 Gy
|
Arm 2-Stereotactic Radiation Dose Level 2
n=3 Participants
Radiation: Stereotactic radiation Arm 2 Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
|
Arm 3-Stereotactic Radiation Dose Level 3
n=3 Participants
Radiation: Stereotactic radiation Arm 3 Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
|
Arm 4-Stereotactic Radiation Dose Level 4
n=3 Participants
Radiation: Stereotactic radiation Arm 4 Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
|
|---|---|---|---|---|
|
Early and Intermediate Toxicity for Dose Limiting Toxicity
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
Adverse Events
Arm 1-Stereotactic Radiation Dose Level 1
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Arm 2-Stereotactic Radiation Dose Level 2
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Arm 3-Stereotactic Radiation Dose Level 3
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Arm 4-Stereotactic Radiation Dose Level 4
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Arm 1-Stereotactic Radiation Dose Level 1
n=3 participants at risk
Radiation: Stereotactic radiation Arm 1 Dose Levels Dose per Fraction Total Dose
1 8 Gy 16 Gy
|
Arm 2-Stereotactic Radiation Dose Level 2
n=3 participants at risk
Radiation: Stereotactic radiation Arm 2 Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
|
Arm 3-Stereotactic Radiation Dose Level 3
n=3 participants at risk
Radiation: Stereotactic radiation Arm 3 Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
|
Arm 4-Stereotactic Radiation Dose Level 4
n=3 participants at risk
Radiation: Stereotactic radiation Arm 4 Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
|
|---|---|---|---|---|
|
Investigations
K(3), AKI secondary to cisplatin nephrotoxicity(5)
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
AKI(2*) RT poor intake, CR(2*) RT poor intake, Fatigue (2*) RT pneumonia or chemo, H/A(2*) related
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
hypoglycemia(2*), chest pain (3*), Hyperglycemia(3*), HGB(2*), CR(1*) k(1*)
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Dyspnea 4*, Tachycardia 2*, Fever 1*cough 1*-
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Bronchopulmonary Hemorrhage (5)
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
upper respiratory infection
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
URI (3*) rt chemo, PLT(2*) PR chemo, hyponatremia (3*) PR chemo, bilateral thigh pain(2*) suspected
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
Other adverse events
| Measure |
Arm 1-Stereotactic Radiation Dose Level 1
n=3 participants at risk
Radiation: Stereotactic radiation Arm 1 Dose Levels Dose per Fraction Total Dose
1 8 Gy 16 Gy
|
Arm 2-Stereotactic Radiation Dose Level 2
n=3 participants at risk
Radiation: Stereotactic radiation Arm 2 Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
|
Arm 3-Stereotactic Radiation Dose Level 3
n=3 participants at risk
Radiation: Stereotactic radiation Arm 3 Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
|
Arm 4-Stereotactic Radiation Dose Level 4
n=3 participants at risk
Radiation: Stereotactic radiation Arm 4 Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
|
|---|---|---|---|---|
|
Investigations
HgB
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
66.7%
2/3 • Number of events 2 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
vomiting
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Creatinine
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
WBC
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
66.7%
2/3 • Number of events 2 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Thrombocytopenia
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
dermatitis
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
pleural effusion
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Lymph
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
66.7%
2/3 • Number of events 2 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
100.0%
3/3 • Number of events 3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Bili
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
dyspnea/hypoxia
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
myalgia
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
esophagitis
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
K
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
ANC
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
cough
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
66.7%
2/3 • Number of events 2 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
fatigue
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
pain- thigh/leg/groin/chest wall
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
nausea
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Ca
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
pneumonitis ,upper respiratory infection (URI),lung Infection (influenza A)
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
AST
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
66.7%
2/3 • Number of events 2 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
ALT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
Magnesium
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
fever
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
diarrhea
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
chills
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
edema
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
|
Investigations
aspiration
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
0.00%
0/3 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
33.3%
1/3 • Number of events 1 • Baseline, 30 days post last dose of SBRT, 12 weeks post last dose of SBRT
|
Additional Information
Thomas DiPetrillo, MD
Brown University Oncology Research Group (BrUOG)
Phone: 4018633000
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place